Meningiomas account for 13-18% of intracranial neoplasms and 25% of intraspinal neoplasms.' Two thirds of meningiomas occur in women,' and for many years it has been known that meningiomas in women may enlarge and become symptomatic during periods of hormonal flux,2 particularly during pregnancy3 and in the luteal phase of the menstrual cycle.4 An increased incidence of meningiomas occurs in women with breast carcinoma,5 a neoplasm that often contains oestrogen receptors and progesterone receptors and which exhibits hormonally dependent growth.6 Oestrogen receptor and progesterone receptor have recently been found in normal leptomeninges,7 the tissue from which meningiomas are thought to arise in man.
These observations have prompted several investigations into the presence of oestrogen receptor and progesterone receptor in meningiomas,8-26 and it has been postulated that the presence of such receptors might be of prognostic and therapeutic value, as for breast carcinoma. All of the assays performed to date have measured oestrogen receptor and progesterone receptor in the cytosol fractions from tissue homogenates of meningiomas. A wide range of results has been obtained, and although an associAccepted for publication 21 August 1985 ation between steroid hormone receptor state and histological subtype of meningioma has been claimed,'920 this observation has not been consistent.2123 Histological typing of meningiomas is usually performed on an adjacent portion of tumour to the sample taken for homogenisation and steroid receptor assay. These two portions of tissue, however, may not be exact replicates as meningiomas are heterogenous neoplasms which may exhibit considerable histological variability.'
We overcame this problem by assaying oestrogen receptor and progesterone receptor in the diffusate of cryostat sections of meningiomas, thus allowing simultaneous histological analysis and steriod hormone receptor assay on adjacent near facsimile samples. This method is based on the observation that unoccupied oestrogen receptor and progesterone receptor readily diffuse from unfixed cryostat sections immersed in an aqueous medium without the need for mechanical homogenisation. [27] [28] [29] Material and methods Forty five consecutive meningiomas were studied from 40 patients (28 women, 12 men) of mean age 55 5 years (age range 33-79). Four patients (three women, one man) had multiple tumours; of these, one 44 Cryostat section assay of oestrogen and progesterone receptors in meningiomas woman came from a family with neurofibromatosis with predominantly central affliction. The site of origin of each neoplasm was identified radiologically and confirmed at the time of surgery.
TISSUE COLLECTION AND STORAGE
Fresh tissue obtained during surgery was trimmed into blocks measuring about 10 x 10 x 5 mm suitable for cryostat microtomy. These were snap frozen and stored at -70°C. Fresh uterus for positive control tissue was obtained from oophorectomised rats for oestrogen receptor assay and from rats killed one week after subcutaneous implantation of a pellet containing 12mg hexoestrol (Boots Company Limited) for progesterone receptor assay. The control tissues were frozen and stored under identical conditions to the meningiomas.
CRYOSTAT SECTIONS AND RECEPTOR ASSAY
Cryostat sections for receptor assay were cut at 40pm, and two additional sections from each block for histology were then cut from the same tissue surface at 6 pm with minimal trimming. Both sections were stained by haematoxylin and eosin to permit classification of the histological subtype of each tumour. This was performed without knowledge of the receptor assay results.
Oestrogen receptor assay was performed on cytosols from the cryostat sections with incubation on ice for one hour with 3H-oestradiol followed by trypsinisation as previously described in a method for breast carcinomas.30 For To investigate the specificity of binding of ORG2058 to cytosolic progesterone receptor incubations of section cytosols with 2 x 10-9 M 3H-ORG2058 were conducted either alone or in the presence of a 100 fold molar excess of either progesterone (Sigma), diethylstilboestrol (Sigma), hydrocortisone (Sigma), or testosterone (Sigma). Incubations were also performed with dexamethasone (Decadron; Merck, Sharp and Dohme) at concentrations of 2 x 10 9M and 10, 100 and 1000 fold molar excess. After incubation for two hours on ice the assay tubes were centrifuged, and the amount of receptor bound 3H-ORG2058 measured.
ISOELECTRIC FOCUSING
Isoelectric focusing was performed on duplicate 100p1 aliquots of cytosol supernatant after incubation with 3H-ORG2058 and dextran coated charcoal. Each sample was pipetted into a plastic application frame (10 x 6 x 2 mm) placed 10 mm from the cathodal electrode strip on the surface of a thin layer polyacrylamide gel (245 x 110 x 1 mm; 2-4% W/V ampholine, pH 3-5-9 5; LKB). The focusing conditions were similar to those used by Underwood et al. 30 After focusing for 90 minutes the gel along each sample track was cut into 5 mm slices, each of which was placed into a scintillation phial, to which was added 4 ml of HP/b scintillant (Beckman). The phials were then incubated in a water bath at 50°C for one hour with gentle agitation.
CALCULATION OF RECEPTOR CONCENTRATION
The radioactivity of each phial was measured by liquid scintillation, counting with quench monitoring by H number (external standard Compton Edge monitoring using '3"Cs). Counting was performed in an LS1801 automated liquid scintillation spectrometer (Beckman). A histogram of radioactivity against gel slice number was plotted for each sample and the cumulative height of the points in the single peak, typically located about 5 cm from the cathodal electrode strip (pH 6 2), was measured above the dia- Fig. 1 shows the results of progesterone receptor assays. Of the 45 neoplasms examined, 24 (53-3%) were positive for progesterone receptor (> 10 fmol/mg cytosol protein). Only one of the neoplasms contained detectable oestrogen receptor at a concentration of 2-3 fmol/mg cytosol protein; this result is not important-that is, (<1O fmol/mg cytosol protein). Of the group of patients with multiple meningiomas, two women had neoplasms both positive and negative for progesterone receptor while one woman had two negative neoplasms for progesterone receptor and the man had two neoplasms positive for progesterone receptor. Fig. 2 shows the results of the diffusion study for progesterone receptor. Rapid diffusion of cytosolic receptor into the aqueous medium necessitates the addition of radiolabelled ligand for progesterone receptor assay as soon as possible after placing the cryostat sections into the buffer and crushing the glass coverslip. Fig. 3 shows the results of the binding study for 3H-ORG2058 and progesterone receptor. An incubation period of two hours was deemed to give the most satisfactory results with this ligand and reflected similar experiences by other workers.33 COMPETITIVE BINDING Fig. 4 shows the results of the competitive binding experiment. No important level of competitive binding was found with any of the steroid hormones other than progesterone; in particular, no competitive binding with dexamethasone was found at any of the concentrations used.
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DIFFUSION AND BINDING STUDIES
SCATCHARD PLOT ANALYSIS Fig. 5 shows the graph obtained from the results of a Scatchard plot analysis. The calculated kD for the reaction is 0 704 nmol/l, indicating a high affinity reaction between the radioligand and the cytosolic progesterone receptor.
TISSUE STORAGE
No important difference between the results of receptor assays repeated on tissues stored for up to six months was found, indicating the stability of cytosolic progesterone receptor at the conditions of storage specified above. homogenates of presumed meningoendotheliomatous meningiomas contain more progesterone receptor than transitional or fibroblastic tumours,'9 but no evidence to support this claim was found in the present study. From our results it seems that there is no relation between the histological subtype of the neoplasm and the steroid hormone receptor state, although it will be necessary to examine more cases of the rarer subtypes to fully assess this relation. The presence of steroid hormone receptors in meningiomas was first investigated in 1979 by Donnell et al who reported the presence of oestrogen receptor in four out of six meningiomas.Y Since then many studies have been published on the presence of oestrogen receptor and progesterone receptor in tissue homogenates from meningiomas.9-26 There is considerable disparity between the published results, some authors claiming to have found an appreciable number of neoplasms that were positive for oestrogen receptor, 8 -1012 141617202326 while others have found that most meningiomas were negative for oestrogen receptor. 1 13151819212225 There does appear to be general agreement that progesterone receptor is present in meningiomas, although the incidence of positive neoplasms varies considerably from series to series. A recent review by Cahill et al found that the results of analysis of steroid hormone receptor in meningiomas fell into two main groups, depending on the presence of clinically important oestrogen receptor. 21 Interestingly, most of the reports describing high concentrations of oestrogen receptor binding in a large proportion of neoplasms originate from France.9122023 Various theories have been put forward to explain this.2123 These include differences in the techniques of tissue biopsy, freezing, duration of storage, and methods of homogenisation. These variables, however, have differed in other reports, which are unanimous in finding low or undetectable concentrations of oestrogen receptor. Another explanation for this discrepancy is the effect of preoperative treatment with dexamethasone on oestrogen receptor and progesterone receptor in meningiomas.12 Poisson et al reported high concentrations of oestrogen receptor in tumours from patients who had been treated preoperatively with glucocorticoids.23 These findings contrast with those from an earlier series from the same laboratory12 and with a series from Sweden,14
HISTOLOGY
Cryostat section assay of oestrogen and progesterone receptors in meningiomas same laboratory12 and with a series from Sweden,'4 in which pretreatment with dexamethasone apparently resulted in considerably lower concentrations of progesterone receptor. All the patients in the present report had received preoperative or intraoperative dexamethasone, and so we were unable to perform a similar comparison. The results of the competitive binding experiment, however, indicate that dexamethasone does not interfere with the progesterone receptor or oestrogen receptor assays used in our experiments.
It has also been suggested that differences in the radiolabelled ligands used in the various reported series might account for the differing results.2" Most of the assays to detect oestrogen receptor have been performed using 3H-oestradiol, although R2858 (11 -beta-methoxy-I 7-beta-ethynylestradiol) was used as the oestrogen analogue by workers in France.9 12 20 It has been suggested that this ligand might offer a more accurate oestrogen receptor assay as it does not bind to human sex hormone binding globulin in the serum, and that binding to such serum proteins may lead to artefactually high results if 3H-oestradiol is used." Surprisingly, the incidence of oestrogen receptor in meningiomas when measured using R2858 is much higher than when 3H-oestradiol has been used. All the previous reports used the synthetic analogue R5020 (3H-promegesterone) as the progesterone analogue in the progesterone receptor assay.8-26 The analogue used in this study 3H-ORG2058 (16 alphaethyl-21-hydroxy-19-nor-[6,7-3H] preg-4-en-3,20 dione) was chosen because of its specific high affinity binding to progesterone receptor, resulting in a stable complex3637 with low cross reactivity with other cytosol receptor sites and with serum corticosteroid binding globulin..37 3H-ORG2058 exhibits lower nonspecific binding than R5020, which may bind weakly to cytosolic glucocorticoid receptors.38 The results of the progesterone receptor assay in this report were broadly similar to those of several previous reports" 181925 although direct comparisons are difficult because of differences in assay technique, measurement of receptors, and interpretation of a significant result.
Schwartz et al in a study of 26 meningiomas confirmed the presence both of oestrogen receptor and progesterone receptor, but because of an apparent lack of steroid binding specificity concluded that the receptor proteins found in meningiomas were unlikely to be specific steroid receptors.24 The results of this and numerous other studies, however, seem to indicate otherwise. It is unlikely that the progesterone receptor activity in our study represents non-specific binding of radioligand to low affinity molecules. Isoelectric focusing is a technique that is eminently suitable for separating receptor bound radioligands from those that are non-specifically bound, especially when working with small volumes as in the technique used in this study.39 The isoelectric focusing profile of progesterone receptor in meningiomas was identical to that obtained in control tissues, and similar results have been obtained from human breast carcinomas.33 Furthermore, the competitive inhibition studies showed the highly specific nature of the cytosolic progesterone receptor in meningiomas. Similar results were obtained by other authors,'520 and Scatchard plot analysis both in this and other reports has further established the high affinity nature of cytosolic progesterone receptor in meningiomas. 15 1920 An analysis of the clinical features of patients whose tumours were studied in this series confirms previous reports that there is no correlation between the presence of progesterone receptor and the age, sex, or menopausal state in the patients studied, or the site of the neoplasm. In the patients with multiple neoplasms it was interesting to note that no generalised predictions could be made regarding the steroid hormone receptor state of the tumours removed. One of the female patients in this series had a familial history of neurofibromatosis with predominantly central manifestations, details of which are published elsewhere.4' The presence of progesterone receptor in patients with multiple, recurrent, or extensively infiltrative neoplasms is of particular interest as it raises the possibility of hormonal manipulation as a form of treatment in adjunct to surgery. This possibility merits investigations in vitro before clinical trials are started.
The presence of cytosolic progesterone receptor in meningiomas in the apparent absence of oestrogen receptor has led to speculation that, in contrast to other cells, the synthesis of progesterone receptor in meningiomas may not be modulated by oestrogens acting through oestrogen receptor.25 Alternatively, it has been suggested that meningiomas containing clinically important quantities of cytosolic progesterone receptor may also contain nuclear oestrogen receptor occupied by endogenous oestrogens which cannot be readily detected by current assay techniques.42 The presence of nuclear oestrogen and progesterone receptor in meningiomas has been reported,26 but the relation of such receptors to free cytosolic receptors remains unclear. Further studies on the presence of nuclear receptors in meningiomas are required before accepting the presence of an oestrogen independent progesterone receptor in these neoplasms. The use of other techniques-for example, cellular localisation of oestrogen receptor using monoclonal antibodies-43 may be of considerable value.
We thank Mr A Buxton and Mr D Brocklehurst for technical help and Mrs P Kirk-for typing the manuscript. Financial support from the Trent Regional Health Authority locally organised NHS research
